Abstract
PURPOSE: Formoterol fumarate inhalation solution (DEY, Napa, CA, USA) has recently been approved in the US for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). We compared the in vitro delivery characteristics of formoterol fumarate via the SideStream® Plus (SSP; Respironics, Inc., Parsippany, NJ, USA) and LC Plus® (LCP; Pari GmbH, Starnberg, Germany) jet nebulizers when run using wall air versus a portable compressor.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
